Remodulin for severe pulmonary arterial hypertension
Treatments studied
Part of Lungs & breathing clinical trials.
This study is testing how safe and effective Remodulin is for people with severe pulmonary arterial hypertension (PAH). You will receive Remodulin as a continuous injection under the skin or into a vein, and the study will monitor your health to see how well it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have pulmonary arterial hypertension (PAH) that causes symptoms like shortness of breath or fatigue, even with minimal activity (WHO class III or IV).
- You are not currently using any other injectable PAH medicine, only Remodulin is allowed.
- You are willing to start treatment with Remodulin, which is given as a continuous injection under the skin or into a vein.
- You can keep scheduled appointments and follow the study instructions.
- You will sign a form saying you understand the study and agree to join.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medicine called treprostinil in children with severe pulmonary arterial hypertension (high blood pressure in the lungs). The study aims to see if it is safe and tolerable for kids who need this kind of therapy.
This study tests whether taking injected treprostinil together with riociguat can improve how the heart and lung blood vessels work in people with advanced pulmonary artery hypertension (PAH). It may help improve blood-flow measurements and the structure of the heart.
This trial tests an inhaled medication (TPIP) that opens blood vessels in the lungs to help you breathe easier and be more active. It is for people with PAH who are already on stable treatment and have moderate symptoms.
This study provides continued access to an investigational inhaled medicine (treprostinil palmitil inhalation powder) for people with pulmonary arterial hypertension (PAH) or pulmonary hypertension linked to interstitial lung disease (PH-ILD) who have already been in earlier studies of this treatment. It allows you to keep receiving the treatment under medical supervision.
This study compares starting treatment with three medicines, including a continuous infusion (treprostinil), versus two oral medicines for people newly diagnosed with moderate-to-high risk pulmonary arterial hypertension (PAH). The goal is to see which approach improves heart function and symptoms more effectively.
This study tests a drug called treprostinil to see if it is safe and effective for people with intermediate-risk pulmonary arterial hypertension (PAH), a condition of high blood pressure in the lungs. If you join, you may receive the study drug along with your usual PAH medications, which could help improve your symptoms and slow the disease.
Hear when a new Pulmonary Arterial Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.